Impact of Knowledge of liver fibrosis on drinking behaviour
Research type
Research Study
Full title
Does knowledge of liver fibrosis affect high-risk drinking behaviour (KLIFAD): Feasibility randomised controlled trial
IRAS ID
273765
Contact name
Mohsan Subhani
Contact email
Sponsor organisation
Nottinghamshire Healthcare NHS Foundation Trust
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Heavy drinkers at risk of liver disease and in contact with alcohol services do not currently have access to testing to establish the severity of their liver disease. Fibroscan is a technology which can now provide this information. It is currently unknown if knowledge of the severity of liver disease in people who are at risk will affect their drinking behaviour. This study sets out to develop standardised fibroscan operator feedback of results and produce video patient stories to enhance feedback and then establish if the approach is feasible and deliverable via a feasibility randomised controlled trial.
The feasibility RCT will be conducted at three community-based alcohol settings hosted by Framework and Nottingham recovery Network and work in partnership with Nottinghamshire NHS foundation trust
• Wellbeing Hub
• Edwin House
• Primary care alcohol clinic run by Nottingham Recovery Network (NRN)
The trial has three work packages (WP),
1. WP1: To establish a standardised script framework
The patient participant will be involved in the focus group to provide feedback on the prototype fibroscan script and Change model questionnaire. The NRN alcohol keyworker in a focus group will give feedback on the final version.
2. WP2: To develop and film video stories using eligible participants
We will record the videos of alcohol recovery stories from participants who have successfully overcome their alcohol use disorder and had fibroscan in past.
3. WP3: As per study protocol test the feasibility randomised control trial design
The Wellbeing Hub and primary care clinic (NHS lead) run 12-week treatment programmes initiated after an initial assessment. The study site staff and/or study team will give patient information to eligible candidates at the initial visit. The baseline visit will be when participant return to start the programme. The next visit will be at 3 months which will be part of routine care. At 6-month participant will be contacted via telephone, or if feasible and participant prefer in-person appointment will be arranged following government COVID guidelines. The participant in the control group will also be offered a fibroscan.REC name
West of Scotland REC 5
REC reference
20/WS/0179
Date of REC Opinion
20 Jan 2021
REC opinion
Further Information Favourable Opinion